Despite the kidney’s tremendous capacity for renal functional reserve (RFR), acute kidney injury (AKI) often leads to chronic kidney disease (CKD). Over 850 million people are affected worldwide. There is a lack of medication potentially able to prevent or stop a deterioration of renal function following acute damage. Modern single-cell transcriptomic technologies bear the potential to fundamentally change our knowledge about disease processes at the cellular level. The project aims to elucidate cellular signatures (“endophenotypes”) of both successful and maladaptive/scarring repair. Its target is to revolutionize classical paradigms of how kidney disease is characterized and consequently lay the groundwork for the development of putative targeted therapies for AKI.

Here you can find further information.